Attached files
| file | filename |
|---|---|
| EX-31.2 - EX-31.2 - Moderna, Inc. | a5exhibit31203312021.htm |
| EX-31.1 - EX-31.1 - Moderna, Inc. | a4exhibit31103312021.htm |
| EX-10.4 - EX-10.4 - Moderna, Inc. | exhibit104directorcompensa.htm |
| EX-10.3 - EX-10.3 - Moderna, Inc. | exhibit103formofpsuagreeme.htm |
| EX-10.2 - EX-10.2 - Moderna, Inc. | exhibit102amendmentno7toba.htm |
| EX-10.1 - EX-10.1 - Moderna, Inc. | exhibit101amendmentno6toba.htm |
| 10-Q - 10-Q - Moderna, Inc. | mrna-20210331.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of Moderna, Inc. (the “Company”) for the period ended March 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, Stéphane Bancel, Chief Executive Officer of the Company, and David W. Meline, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of our knowledge:
1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| Date: May 6, 2021 | By: | /s/ Stéphane Bancel | |||||||||
| Stéphane Bancel | |||||||||||
| Chief Executive Officer | |||||||||||
| (Principal Executive Officer) | |||||||||||
| Date: May 6, 2021 | By: | /s/ David W. Meline | |||||||||
| David W. Meline | |||||||||||
| Chief Financial Officer | |||||||||||
| (Principal Financial Officer) | |||||||||||